- Home
- MRKR vs IBIO Comparison
MRKR vs IBIO Comparison
Compare MRKR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- IBIO
- Stock Information
- Founded
- MRKR N/A
- IBIO 2008
- Country
- MRKR United States
- IBIO United States
- Employees
- MRKR N/A
- IBIO N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- IBIO Health Care
- Exchange
- MRKR Nasdaq
- IBIO Nasdaq
- Market Cap
- MRKR 13.7M
- IBIO 11.9M
- IPO Year
- MRKR N/A
- IBIO N/A
- Fundamental
- Price
- MRKR $0.89
- IBIO $0.81
- Analyst Decision
- MRKR Strong Buy
- IBIO Strong Buy
- Analyst Count
- MRKR 3
- IBIO 2
- Target Price
- MRKR $13.17
- IBIO $5.50
- AVG Volume (30 Days)
- MRKR 2.6M
- IBIO 2.1M
- Earning Date
- MRKR 08-14-2025
- IBIO 09-19-2025
- Dividend Yield
- MRKR N/A
- IBIO N/A
- EPS Growth
- MRKR N/A
- IBIO N/A
- EPS
- MRKR N/A
- IBIO N/A
- Revenue
- MRKR $5,388,071.00
- IBIO $375,000.00
- Revenue This Year
- MRKR N/A
- IBIO N/A
- Revenue Next Year
- MRKR $15.82
- IBIO N/A
- P/E Ratio
- MRKR N/A
- IBIO N/A
- Revenue Growth
- MRKR 44.55
- IBIO 650.00
- 52 Week Low
- MRKR $0.81
- IBIO $0.56
- 52 Week High
- MRKR $5.95
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- MRKR 30.85
- IBIO 58.32
- Support Level
- MRKR $0.81
- IBIO $0.67
- Resistance Level
- MRKR $0.98
- IBIO $0.85
- Average True Range (ATR)
- MRKR 0.10
- IBIO 0.09
- MACD
- MRKR -0.03
- IBIO 0.02
- Stochastic Oscillator
- MRKR 14.39
- IBIO 63.45
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.